The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
MiR-198 sensitizes pancreatic cancer to gemcitabine treatment through downregulation of VCP-mediated autophagy maturation.
 
Christian Marín-Müller
Employment - Speratum Biopharma, Inc.
Leadership - Speratum Biopharma, Inc.
Stock and Other Ownership Interests - Speratum Biopharma, Inc.
Research Funding - Speratum Biopharma, Inc.
Patents, Royalties, Other Intellectual Property - Patents
Travel, Accommodations, Expenses - Speratum Biopharma, Inc.
 
Dali Li
No Relationships to Disclose
 
Jian-Ming Lu
No Relationships to Disclose
 
Zhengdong Liang
No Relationships to Disclose
 
Osvaldo Vega-Martínez
Employment - Speratum Biopharma, Inc.
Research Funding - Speratum Biopharma, Inc.
Travel, Accommodations, Expenses - Speratum Biopharma, Inc.
 
William Fisher
No Relationships to Disclose
 
Changyi Chen
No Relationships to Disclose
 
Qizhi Cathy Yao
No Relationships to Disclose